Human Anti-HIV-1 Env Recombinant Antibody (clone CAP228-3D) (CAT#: PABC-420)

Figure 1 CAP228 antibodies efficiently inhibit α4β7 integrin binding.

Inhibition of ConC gp120 binding to α4β7 integrin transfected 293 T cells by V2p mAbs CAP228-16H (green), CAP228-3D (orange) or CH58 (blue). Percentage blocking (y-axis) was calculated from the difference in mean fluorescence intensity (MFI) when cell-gp120 complexes were made in the presence or absence of antibody. The α4β7 specific antibodies HP21 (purple) and ACT1 (red) were used as positive controls, while an irrelevant RSV antibody (palivizumab) and an HIV-1 CD4 binding site-specific antibody (VRC01) were used as the negative controls.

Wibmer, C. K., Richardson, S. I., Yolitz, J., Cicala, C., Arthos, J., Moore, P. L., & Morris, L. (2018). Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions. Nature communications, 9(1), 4489.

Figure 2 Endpoint ELISA binding titres of V2p mAbs CAP228-16H (green), CAP228-3D (orange) or CH59 (light blue), quaternary structure dependent V2q mAb PGT145 (purple) or V2i mAb 830 A (yellow) to concentrated pseudovirus expressing the C1080 envelope.

HIV-1 CD4 binding site-specific antibody VRC01, and an irrelevant Flu-specific antibody were used as positive or negative controls, respectively.

Wibmer, C. K., Richardson, S. I., Yolitz, J., Cicala, C., Arthos, J., Moore, P. L., & Morris, L. (2018). Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions. Nature communications, 9(1), 4489.